Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | Navigating neuroprotection in stroke care: insights and challenges

James Grotta, MD, Memorial Hermann-Texas Medical Center, Houston, TX, reviews recent findings in the field of neuroprotection for stroke care. Notably, newly presented ESCAPE-NEXT data on nerinetide, a first-in-class peptide inhibitor of PSD-95, did not show clear benefits, failing to establish nerinetide as superior in improving stroke outcomes compared to controls. However, the parallel FRONTIER trial did indicate a large treatment effect when nerinetide was administered within 60 minutes of symptom onset. Group imbalances and a small sample size complicate the interpretation of these findings. Dr Grotta suggests a shift towards therapies addressing downstream effects, particularly inflammation. While the success of reperfusion continues to dominate the field, the neuroprotection space still requires further exploration. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


James Grotta reports the following disclosures: I am on the scientific advisory board for Acticor, and am U.S. Principle Investigator for the ACTISAVE study. Acticor manufactures Glenzocimab. I am a consultant for Frazer Ltd, a company that manufactures Mobile Stroke Units.